A Phase Ii Study of Biweekly Oxaliplatin and S-1(Sox) As First-Line Combination Therapy in Patients with Advanced Gastric Cancer.
Jing Deng,Genming Shi,Yulong Zheng,Jiong Qian,Haiping Jiang,Chenyu Mao,Xiaochen Zhang,Yao Wang,Nong Xu
DOI: https://doi.org/10.1200/jco.2015.33.15_suppl.e15094
IF: 45.3
2015-01-01
Journal of Clinical Oncology
Abstract:e15051 Background: Paclitaxel and S-1 are both effective anti-tumor agents in advanced gastric cancer. However, the continuous administration of S-1 for three weeks or more can result in unacceptable toxicities. Therefore, an alternative treatment schedule (one-week administration followed by a one-week rest) is warrant for testing in order to allow continuation of the therapy. We evaluate the efficacy and safety of biweekly paclitaxel and S-1(SPA) as first-line combination therapy in patients with metastatic or locally advanced gastric cancer. Methods: Forty-four Chinese patients(pts) have been included. 33 were male and 11 were female. Median age was 60 years (24-78). 90.1% had ECOG 0 and 1 and. 9 (20.4%) had locally advanced disease and 35 (79.6%) metastatic disease. Pts were administered intravenously paclitaxel at a dose of 120 mg/m2 on day 1 and oral S-1 twice daily (BSA < 1.25 m2, 80 mg/day; 1.25 < or = BSA < 1.50 m2, 100 mg/day; 1.50 m2< or = BSA, 120 mg/day) on days 1-7 followed by a drug-free interval of 1 week every 14-day cycle. A total of 277 chemotherapy cycles were administered, with a median of 6 cycles per patient (range 1-12), and 19 (43.2%) pts received up to seven cycles. 34 pts (77.2%) received second-line treatment. Results: Of the 44 eligible pts, the ORR was 38.6% with PR in 17 pts, SD in 20 pts s and PD in 6 pts. The median PFS and median OS were 5.2 months (95% CI: 4.08-6.39 months) and 12.2 months (95% CI: 8.81-15.60 months) , respectively, The major hematological toxicities were grade 3 leucocytopenia in 2 pts (4.5%), grade 3 neutropenia in 14 pts (40.9%) and grade 4 in 4 pts (9.0%). Two pts (4.5%) suffered grade 1 febrile neutropenia. The grade 3/4 nonhematological toxicities, such as nausea, vomiting, alopecia, diarrhea, neurological toxicity and fatigue accounted for 4.5%, 6.8%, 4.5%, 2.2%, 2.2% and 6.8%, respectively. Conclusions: Biweekly paclitaxel and S-1(SPA regimen) combination therapy had promising activity with acceptable toxicities. SPA regimen was easy to implement and more patients received second-line chemotherapy. A well-designed randomized phase III study is needed to compare this regimen with other S-1-based combination treatments. Clinical trial information: 85705844.